Mark Leuchtenberger

Melinta Subsidiary Corp. develops and markets pharmaceutical products for the treatment of life-threatening infections. It also develops novel classes of antibiotics to treat the multi- and extremely-drug-resistant pathogens for which there are few to no options, known collectively as ESKAPE pathogens. The company was founded by John N. Abelson, Harry F. Noller, Susan Froshauer, Harry H. Penner, Jr., William L. Jorgensen, Thomas A. Steitz, and Peter Moore in October 2000 and is headquartered in New Haven, CT.

Therion Biologics Corp. developed therapeutic vaccines for cancer patients. The company was founded on May 5, 1991 and was headquartered in Cambridge, MA.

Beth Israel Deaconess Medical Center provides medical services. It offers patient care, biomedical research, teaching, and community services. It also provides organ transplantation, breast cancer care, and cardiac surgery services. The company was founded in 1896 and is headquartered in Boston, MA.

Massachusetts Biotechnology Council is a premier life sciences and healthcare hub with over 1,600 members dedicated to preventing, treating, and curing diseases through transformative science and technology. The non-profit company is based in Cambridge, MA. MassBio works to advance policy and promote education while providing member programs, events, industry information, and services. The company's mission is to advance Massachusetts' leadership in the life sciences to grow the industry, add value to the healthcare system, and improve patient lives. Founded in 1985 by James P. Sherblom, the CEO is Kendalle Burlin O'Connell.

NeuroHealing Pharmaceuticals, Inc. develops drug therapies for the post-acute and chronic neuro-rehabilitation patients. Its products include NH001, a dopaminergic agent to help post traumatic brain injury patients to emerge from a coma, vegetative, or minimally consciousness state, NH004, a treatment for the social debilitating condition of sialorrhea, a non-motor complaint of Parkinson's disease patients and NH02D, an orally administered drug for on-demand treatment of premature ejaculation, a male sexual disorder affecting sexually active men. The company was founded by Esteban Fridman and Daniel Katzman in 2003 and is headquartered in Waban, MA.

Part of Arrowhead Pharmaceuticals, Inc., Alvos Therapeutics, Inc. develops novel cancer drugs. The company is based in Wellesley, MA. The company was founded by Mark Wayne Leuchtenberger. Alvos Therapeutics was acquired by Arrowhead Pharmaceuticals, Inc. on April 11, 2012 for $25.50 million.

Spybiotech Ltd. develops molecular superglue which it believes can be used to create vaccines. The company was founded by Sumit Biswas and is headquartered in Oxford, the United Kingdom.

Part of Eterna Therapeutics, Inc., Eterna Therapeutics LLC is a clinical-stage biopharmaceutical company based in New York, NY. The company is focused on exploring the role that cytokine-based therapy can have on the immune system in treating patients with cancer. Eterna Therapeutics is committed to developing irx-2, a novel cytokine-based therapy, to treat patients with cancer. The active constituents of irx-2, namely interleukin-2 (il-2) and other key cytokines, are postulated to signal, enhance and restore immune function suppressed by the tumor, thus enabling the immune system to attack cancer cells. Eterna Therapeutics is a late clinical-stage biopharmaceutical company focused on il-2 cytokine-based therapies in treating patients with cancer. Eterna Therapeutics was acquired by NTN Buzztime, Inc. on March 25, 2021 for $213.30 million.

Aleta Biotherapeutics, Inc. engages in the immuno-oncology service that focuses on transforming cellular therapeutics. It allows broad spectrum of cancer indication to be targeted including currently intractable solid tumors. The company was founded by Paul Rennert and Roy Lobb and is headquartered in Natick, MA.